Select Equity Group L.P. Has $9.84 Million Holdings in Lantheus Holdings, Inc. $LNTH

Select Equity Group L.P. boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 899.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 100,843 shares of the medical equipment provider's stock after buying an additional 90,751 shares during the period. Select Equity Group L.P. owned approximately 0.15% of Lantheus worth $9,842,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. State of Michigan Retirement System raised its position in Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock valued at $1,620,000 after buying an additional 100 shares during the period. Signaturefd LLC grew its stake in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 116 shares in the last quarter. Intrust Bank NA grew its stake in Lantheus by 2.9% in the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock valued at $431,000 after purchasing an additional 125 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Lantheus by 2.1% in the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after purchasing an additional 139 shares in the last quarter. Finally, Moody National Bank Trust Division grew its stake in Lantheus by 1.0% in the first quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock valued at $1,455,000 after purchasing an additional 141 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Lantheus

In other Lantheus news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,812,000 shares of company stock valued at $382,427,380. Insiders own 1.50% of the company's stock.

Lantheus Stock Performance

NASDAQ:LNTH traded down $2.05 during mid-day trading on Friday, hitting $52.94. 842,370 shares of the company's stock traded hands, compared to its average volume of 1,507,125. The firm has a 50 day moving average of $63.98 and a two-hundred day moving average of $81.27. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $118.21. The firm has a market capitalization of $3.60 billion, a price-to-earnings ratio of 14.08 and a beta of 0.15. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $378.05 million for the quarter, compared to the consensus estimate of $389.69 million. During the same quarter in the previous year, the company earned $1.80 EPS. Lantheus's revenue for the quarter was down 4.1% compared to the same quarter last year. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the topic of a number of recent research reports. Truist Financial set a $63.00 target price on Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. JMP Securities lowered their target price on Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. B. Riley decreased their price target on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Finally, Mizuho decreased their price target on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $91.60.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.